Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD79 antibody
- Development stage
- Preclinical
- Lead developer
- Nepenthe Bioscience
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Oral, Topical, Subcutaneous, Intravenous, Intramuscular, Intranasal, Intradermal, Intrathecal, Intraperitoneal, Intra-arterial, Parenteral
01
Overview
CD79 antibody is a monoclonal antibody currently under development by Nepenthe LLC, a biotechnology company incubated by Panorama Research. The therapeutic candidate is designed to target CD79, a signaling component of the B-cell receptor (BCR) complex that is expressed exclusively on the surface of B-cells and their precursors. By binding to CD79, the antibody aims to modulate B-cell activity or induce B-cell depletion, offering a potential treatment strategy for various immunological and autoimmune diseases where B-cell dysregulation plays a central role. The program is currently in the early stages of development.
- Other names
- CD79 monoclonal antibodyCD-79 monoclonal antibodyCD 79 monoclonal antibodyanti-CD79 antibodyanti-CD-79 antibodyanti-CD 79 antibody
02
Targets
CD79 (B-cell antigen receptor complex-associated protein alpha and beta subunits)
Beyond the preview
Go deeper on CD79 antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD79 antibody.